Check-Cap (NASDAQ:CHEK) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Check-Cap (NASDAQ:CHEK) in a report released on Sunday. The brokerage set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Down 4.0 %

CHEK stock opened at $0.77 on Friday. The firm has a 50 day moving average of $1.05 and a two-hundred day moving average of $1.19. Check-Cap has a 12 month low of $0.56 and a 12 month high of $3.45. The company has a market capitalization of $4.51 million, a price-to-earnings ratio of -0.26 and a beta of 0.19.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.